Actively Recruiting
Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2024-11-29
100
Participants Needed
1
Research Sites
573 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.
CONDITIONS
Official Title
Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients received anti-HBV therapy with nucleos(t)ide analogs.
- Last anti-HBV therapy should continue for at least 2 years.
- For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after HBeAg seroconversion before therapy ending.
- For HBeAg negative patients, HBV DNA should keep negative for at least 2 years before therapy ending.
You will not qualify if you...
- Liver cirrhosis or hepatocellular carcinoma (HCC).
- Other factors causing active liver diseases.
- Pregnancy or lactation.
- HIV infection or congenital immune deficiency diseases.
- Severe diabetes, autoimmune diseases, important organ dysfunctions, or other serious complications.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
Actively Recruiting
Research Team
W
Wenxiong Xu, Master
CONTACT
L
Liang Peng, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here